XML 64 R54.htm IDEA: XBRL DOCUMENT
v3.25.2

Option Agreements and License Agreements (Details) - USD ($) $ in Millions | 1 Months Ended | 2 Months Ended | 3 Months Ended | 5 Months Ended | 6 Months Ended | 11 Months Ended | 12 Months Ended
--- | --- | --- | --- | --- | --- | --- | ---
Jul. 31, 2025 | Jun. 30, 2024 | Jun. 30, 2025 | Jun. 30, 2024 | Jun. 30, 2024 | Jun. 30, 2025 | Dec. 31, 2024 | Dec. 31, 2025
Option Agreements and License Agreements [Line Items] |  |  |  |  |  |  |  |
Non-refundable milestone payments |  |  |  |  |  | $ 4.0 |  |
Expenses |  |  | $ 4.2 | $ 15.4 | $ 20.4 | 5.7 |  |
Paruka Warrant Obligation [Member] |  |  |  |  |  |  |  |
Option Agreements and License Agreements [Line Items] |  |  |  |  |  |  |  |
Warrant purchase percentage |  |  |  |  |  |  | 1.00% | 1.00%
ORKA-002 [Member] |  |  |  |  |  |  |  |
Option Agreements and License Agreements [Line Items] |  |  |  |  |  |  |  |
Non-refundable milestone payments | $ 3.0 |  |  |  |  |  |  |
Milestone consideration paid |  |  | 2.5 |  |  | 2.5 |  |
Research and development expenses |  |  |  | $ 2.7 | 6.9 | $ 0.1 |  |
ORKA-001 [Member] |  |  |  |  |  |  |  |
Option Agreements and License Agreements [Line Items] |  |  |  |  |  |  |  |
Development costs |  |  |  |  |  | 50.00% |  |
Research and development expenses |  | $ 12.4 |  |  | $ 13.2 |  |  |
Related Party [Member] | ORKA-002 [Member] |  |  |  |  |  |  |  |
Option Agreements and License Agreements [Line Items] |  |  |  |  |  |  |  |
Accounts payable and other current liabilities |  |  |  |  |  |  | $ 2.7 |
Related Party [Member] | ORKA-001 [Member] |  |  |  |  |  |  |  |
Option Agreements and License Agreements [Line Items] |  |  |  |  |  |  |  |
Accounts payable and other current liabilities |  |  |  |  |  |  | $ 12.4 |
Paragon [Member] | Antibody Products [Member] |  |  |  |  |  |  |  |
Option Agreements and License Agreements [Line Items] |  |  |  |  |  |  |  |
Royalty payable on product sales, description |  |  |  |  |  |  | low single-digit percentage royalty for antibody products |
Paragon [Member] | ORKA-002 [Member] | Research and Development Expense [Member] | Achievement Of Development Candidate [Member] |  |  |  |  |  |  |  |
Option Agreements and License Agreements [Line Items] |  |  |  |  |  |  |  |
Milestone consideration paid |  |  |  |  |  |  | $ 1.5 |
Paragon [Member] | ORKA-002 [Member] | Research and Development Expense [Member] | Exercising Option [Member] |  |  |  |  |  |  |  |
Option Agreements and License Agreements [Line Items] |  |  |  |  |  |  |  |
Nonrefundable research initiation fee |  |  |  |  |  |  | 0.8 |
Paragon [Member] | ORKA-001 [Member] |  |  |  |  |  |  |  |
Option Agreements and License Agreements [Line Items] |  |  |  |  |  |  |  |
Nonrefundable research initiation fee |  |  |  |  |  |  | 0.8 |
Paragon [Member] | ORKA-001 [Member] | Research and Development Expense [Member] | Achievement Of Development Candidate [Member] |  |  |  |  |  |  |  |
Option Agreements and License Agreements [Line Items] |  |  |  |  |  |  |  |
Milestone consideration paid |  |  |  |  |  |  | 1.5 |
Paragon [Member] | ORKA-001 [Member] | Research and Development Expense [Member] | First Dosing of Human Patient in Phase1Trial Milestone [Member] |  |  |  |  |  |  |  |
Option Agreements and License Agreements [Line Items] |  |  |  |  |  |  |  |
Milestone consideration paid |  |  |  |  |  |  | 2.5 |
Maximum [Member] | Paragon [Member] | Clinical Development Milestones [Member] |  |  |  |  |  |  |  |
Option Agreements and License Agreements [Line Items] |  |  |  |  |  |  |  |
Non-refundable milestone payments |  |  |  |  |  |  | 12.0 |
Maximum [Member] | Paragon [Member] | Regulatory Milestones Member [Member] |  |  |  |  |  |  |  |
Option Agreements and License Agreements [Line Items] |  |  |  |  |  |  |  |
Non-refundable milestone payments |  |  |  |  |  |  | 10.0 |
Maximum [Member] | Paragon [Member] | ORKA-002 [Member] | Clinical Development Milestones [Member] |  |  |  |  |  |  |  |
Option Agreements and License Agreements [Line Items] |  |  |  |  |  |  |  |
Non-refundable milestone payments |  |  |  |  |  |  | $ 12.0 |

X
- Definition class of warrant or right to purchase percentage of outstanding diluted stock maximum. + References No definition available. + Details
Name: | orka_ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum
Namespace Prefix: | orka_
Data Type: | dtr:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Development cost. + References No definition available. + Details
Name: | orka_DevelopmentCost
Namespace Prefix: | orka_
Data Type: | dtr:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of milestone consideration paid. + References No definition available. + Details
Name: | orka_MilestoneConsiderationPaid
Namespace Prefix: | orka_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Non refundable initiation fee. + References No definition available. + Details
Name: | orka_NonRefundableInitiationFee
Namespace Prefix: | orka_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Non-refundable milestone payments. + References No definition available. + Details
Name: | orka_NonRefundableMilestonePayments
Namespace Prefix: | orka_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Royalty payable on product sales, description. + References No definition available. + Details
Name: | orka_RoyaltyPayableOnProductSales
Namespace Prefix: | orka_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_AccountsPayableOtherCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of expense classified as other. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 944 -SubTopic 605 -Name Accounting Standards Codification -Section 55 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 944 -SubTopic 605 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details
Name: | us-gaap_OtherExpenses
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of other research and development expense. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1 + Details
Name: | us-gaap_OtherResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_ClassOfWarrantOrRightAxis=orka_ParukaWarrantObligationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=orka_ORKAZeroZeroTwoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=orka_ORKAZeroZeroOneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=us-gaap_RelatedPartyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=orka_ParagonMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=orka_AntibodyProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=orka_AchievementOfDevelopmentCandidateMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=orka_ExercisingOptionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=orka_FirstDosingOfHumanPatientInPhaseOneTrialMilestoneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=orka_ClinicalDevelopmentMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=orka_RegulatoryMilestonesMemberMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |